Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients is a phase 3, randomised interventional study registered as NCT04246684 by Prof. Dr. med. Claus Rödel, with a registry enrolment figure of 702 participants, started 2020-11-05 and due to reach its primary completion in 2026-09-15. Interventions recorded: Oxaliplatin, 85 mg/m2; 5FU; 2400 mg/m2; 5FU, 250 mg/m2; 5FU, 2400 mg/m2; Oxaliplatin 50 mg/m2; Folinic Acid, 400 mg/m2; Radiotherapy control, 5x5 Gy: 25 Gy; Capecitabine, 1000 mg/m2; Oxaliplatin 85 mg/m2; radiotherapy experimental, 30 x 1,8 Gy: 54 Gy; Capecitabine, 825 mg/m2; Oxaliplatin, 130 mg/m2. Conditions listed: Rectal Cancer Stage III. Primary outcome: organ preservation. Colorectal eligibility wording from the registry: "* diagnosis of rectal adenocarcinoma localised 0 - 12 cm from the anocutaneous line as measured by rigid rectoscopy (i". Sites: Germany. No results are recorded here; the registry entry is the source.